How Is Multiple Myeloma (MM) Treated?
Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
Multiple myeloma gets new attention after Bruce Springsteen's wife reveals diagnosis
Patti Scialfa, Bruce Springsteen’s wife and bandmate, said she has multiple myeloma. Here's what to know about the blood ...
Multiple myeloma, rare blood cancer: Bruce Springsteen's wife's diagnosis spotlights the illness
Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...
Patti Scialfa's Cancer Diagnosis: What To Know About Multiple Myeloma
Patti Scialfa, Bruce Springsteen’s Wife and E Street Bandmate, has been diagnosed with multiple myeloma. Find out more on ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Zacks.com on MSN18h
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa ...
The American Journal of Managed Care10d
CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM
Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, ...
Monthly Prescribing Reference18h
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...
FiercePharma3d
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
The American Journal of Managed Care3d
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
Cure Today4d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The median progression-free survival (PFS, the time a patient lives without their ... in 2020 in combination with ...
Targeted Oncology3d
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...